Macro● Neutral
OneSource Specialty Pharma to Make Biosimilars for Formycon AG
OneSource Specialty Pharma will manufacture biosimilars for Formycon AG. The deal strengthens Formycon's supply chain and signals growing demand for biologics contract manufacturing.
Continue with
OneSource Specialty Pharma will manufacture biosimilars for Formycon AG under a new partnership, the companies said. The deal gives Formycon access to OneSource's integrated production capabilities for biologic copycat drugs.
Formycon's chief executive said the arrangement strengthens the company's supply chain with a partner focused on quality. The two firms said they want to broaden global access to biosimilar therapies, which are lower-cost alternatives to branded biologics.